Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Celltex Therapeutics has initiated talks with the US Food and Drug Administration (FDA) to conduct a study of adult, autologous mesenchymal stem cells (MSCs) for the treatment of Covid-19 symptoms.
The company assessed the safety and efficacy of MSCs in people with injuries, pain and conditions associated with autoimmune, vascular and other diseases such as pneumonia.
Celltex, in alliance with the Texas A&M University Institute for Regenerative Medicine, evaluated MSCs in Covid-19 patients.
Data from this study showed that intravenous administration of clinical-grade human MSCs led to improved functional outcomes.